Novo Nordisk to sell Wegovy pill to US self-pay patients starting at $149 per month
COPENHAGEN, Jan 5 (Reuters) – Denmark’s Novo Nordisk said on Monday it will offer 1.5- and 4-milligram Wegovy weight-loss pills to self-pay patients in the United States starting Jan. 5 for $149 a month.
Starting on the same date, it will offer the highest doses of the pill (9 and 25 milligrams) for $299 per month, the website said.
It was stated that the price of the 4-milligram dose will increase to $199 per month as of April 15.
Advertising
Advertising
The U.S. Food and Drug Administration approved the pill on Dec. 22, giving Novo Nordisk a boost as it tries to regain lost ground from rival Eli Lilly.
Semaglutide pills contain the same active ingredient as the injectable Wegovy and Ozempic and will be sold under the brand name Wegovy. Novo Nordisk already sells Rybelsus, an oral semaglutide for type 2 diabetes.
(Reporting by Jacob Gronholt-Pedersen, writing by Anna Ringstrom, editing by Terje Solsvik)
